A novel functional drink with nutraceutical properties was formulated from the aqueous extracts of Ilex guayusa, and Vernonanthura patens leaves, and cocoa husks. This combination presents bioactive compounds, such as phenolic compounds, with antioxidant properties of pharmacological interest. However, it is known that the interaction of herbal extracts compounds may cause adverse toxic effects on human health. To evaluate this functional drink's innocuity, we estimated the acute oral toxicity in experimental mice. The toxicological study was carried out following the FASEB Statement of Principles for the Use of Animals in Research and Education. Female albino mice were treated with a single oral dose (2000 mg/kg of body weight) of the aqueous extract of the functional drink's two formulations. In addition, changes in behavior, body weight, food and water consumption, and histopathological studies were evaluated. No signs of adverse toxicity and mortality were observed after a single oral dose of 2000 mg/kg b.w. Likewise, there were no significant body and organ weight changes, food and water consumption behavior, and no histopathological changes were observed in the main organs evaluated. In conclusion, this functional drink can be categorized as “non‐toxic,” according to the Globally Harmonized Classification System (GHS), making it a potent antioxidant beverage with high nutritional value.

Rheumatoid Arthritis is a Systemic Autoimmune Disease in which the main character is to cause an inflammation in the synovial membrane that protects and lubricates the joints causing pain, swelling, stiffness, and loss of functions, and progressive destruction in different degrees. For some years now, biological medicines have been used in the treatment of rheumatic diseases. Despite the critical benefits they provide, they carry harmful side effects. This work aims to compare the adverse events reported in the Uppsala VigiAccess database and the scientific literature reviews that describe the adverse events in using the drug Tocilizumab. A systemic review of scientific articles corresponding to the administration and adverse effects of Tocilizumab was carried out, using scientific bases such as Google Scholar, ClinicalKey, PubMed, Scopus, and the comparison of adverse events reported in the VigiAccess database. As a results, the data obtained according to the VigiAccess database indicates that the population between 40 and 64 years of age is the most prone to suffer adverse reactions to Tocilizumab, with a value of 11,756 reported cases; this differs from what is observed in scientific publications, where the age group 65‐74 years was the most prone to adverse reactions, followed by the 45‐64 year group (3,881 and 581 cases, respectively). It is recommended to observe the Reports' Analysis to gather the necessary information to identify the most common adverse events to medications during the treatments with Tocilizumab; developing informative and educational strategies aimed at health personnel and patients for their prevention.